The Seoul Metropolitan Government has invested 13.8 billion won in the Seoul BioHub, a specialized facility in Hongneung dedicated to fostering the biotech and medical industries. This initiative aims to support promising startups throughout their entire development cycle—from discovery and funding to open innovation and global expansion.
Since its establishment eight years ago, Seoul BioHub has nurtured 316 bio and medical startups, generating a significant economic impact: 98 billion won in corporate sales, 492.5 billion won in attracted investments, and 1,967 new jobs.
To further drive innovation, Seoul BioHub operates seven key programs
- Startup Incubation – Provides workspace and tailored support for 27 selected bio-medical startups within the BioHub.
- Practical Training – Offers specialized training programs for industry professionals and startup founders to enhance their expertise.
- Technical Advisory – Connects startups with industry experts through the Science Advisory Board (SAB), facilitating mentorship and collaborative research.
- Open Innovation Partnerships – Promotes R&D collaboration with institutions like the University of Basel and major pharmaceutical companies such as Celltrion, Daewon Pharmaceutical, Medytox, as well as global leaders BMS, Novartis, and Roche.
- Global Conference Participation – Supports startups in attending major international events, including BIO USA (June 2025) and HLTH (October 2025).
- Global Expansion – Provides overseas acceleration opportunities and attracts high-potential foreign startups.
- Research Infrastructure – Offers access to cutting-edge research facilities across five buildings, featuring 28 specialized rooms and 109 types of research equipment.
The Seoul Metropolitan Government is committed to strengthening its support for innovative startups, helping them overcome industry challenges and positioning the bio-medical sector as a key driver of Seoul’s future growth.
